How treatment delay may lead to loss of effectiveness of tranexamic acid
ANZ J Surg
.
2020 Apr;90(4):416-418.
doi: 10.1111/ans.15669.
Authors
Matthew Locke
1
,
Colin Longstaff
1
Affiliation
1
Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC), Herts, UK.
PMID:
32339423
DOI:
10.1111/ans.15669
No abstract available
MeSH terms
Antifibrinolytic Agents* / therapeutic use
Blood Loss, Surgical
Humans
Time-to-Treatment
Tranexamic Acid* / therapeutic use
Treatment Outcome
Substances
Antifibrinolytic Agents
Tranexamic Acid